(Q43567807)

English

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment

scientific article published on 11 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Hirotsugu Imaeda

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hirotsugu Imaeda

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Shigeki Bamba

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Kenichiro Takahashi

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Takehide Fujimoto

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Hiromitsu Ban

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Tomoyuki Tsujikawa

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Masaya Sasaki

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Yoshihide Fujiyama

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Akira Andoh

10

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

11 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

674-682

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Evolving paradigms in the pathogenesis of IBD.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Clinical scenarios in IBD: optimizing the use of conventional and biologic agents

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Assessing response and loss of response to biological therapies in IBD.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Mucosal healing in inflammatory bowel diseases: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0829-7

21 January 2018

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictability of the postoperative course of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endoscopic monitoring of infliximab therapy in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23666424

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-013-0829-7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43567807&oldid=2101159465"